Oncothyreon Reports Full Year and Fourth Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Jefferies Starts Oncothyreon (ONTY) at Buy; Sees 49% Upside
March 12, 2015 6:42 AM EDTJefferies initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and a price target of $2.50, suggesting 49% upside to yesterday's close.
Analyst Biren Amin commented, "ONTY's ONT-380 has shown encouraging efficacy in PI trials and differentiates itself from competitors on safety. ONTY is further... More
Oncothyreon (ONTY) Misses Q4 EPS by 21c
March 10, 2015 4:02 PM EDTOncothyreon (NASDAQ: ONTY) reported Q4 EPS of ($0.30), $0.21 worse than the analyst estimate of ($0.09).
As of December 31, 2014, Oncothyreon's cash, cash equivalents and investments were $63.7 million, compared to $72.6 million at December 31, 2013, a decrease of $8.9 million, or 12.3 percent. The decrease was primarily attributable to $48.4... More
